Microarray-Based vs. Column-Based Gene Fragment Synthesis: A Technical Comparison

When ordering synthetic gene fragments, most researchers focus on the end product — sequence accuracy, turnaround time, and price per base pair. Far fewer consider the underlying synthesis platform that produces those fragments, yet this choice has profound implications for scalability, cost structure, and the range of projects a provider can support. Two fundamentally different manufacturing technologies dominate the gene fragment synthesis industry today: microarray-based (array-based) synthesis and traditional column-based phosphoramidite synthesis. Understanding how each platform works, and where each excels or falls short, enables researchers and procurement teams to make more informed supplier decisions — and to choose a synthesis mode that aligns with their project's true requirements.

The Foundations: How Each Platform Works

Column-Based Phosphoramidite Synthesis

Column-based synthesis — also known as solid-phase phosphoramidite chemistry — has been the workhorse of the oligonucleotide industry for over four decades. In this approach, a single oligonucleotide sequence is synthesized on a solid resin support contained within a small column. Synthesis proceeds in a stepwise, 3′-to-5′ direction, adding one nucleotide per cycle through four chemical steps: detritylation, coupling, capping, and oxidation.

Key characteristics of column-based synthesis:

• Each column produces one sequence at a time — parallelism is achieved by running many columns simultaneously, but each column is dedicated to a single oligo
• Coupling efficiency per step is typically 98–99.5%, which means that for a 100-mer oligo, approximately 13–40% of molecules will contain at least one error
• HPLC or PAGE purification is routinely applied to individual oligos, enriching for full-length, correct sequences and achieving purities of > 90% for standard oligos
• Synthesis scale ranges from nanomoles to micromoles per column, making column synthesis excellent for producing large quantities of a single sequence
• Maximum practical oligo length is approximately 150–200 nt for high-quality synthesis, though providers can extend to 300+ nt with reduced purity

Column-based synthesis is the gold standard for individual oligo production — primers, probes, single guide RNAs, antisense oligonucleotides, and other applications where high purity and large quantities of a single sequence are required.

Microarray-Based (Array-Based) Synthesis

Microarray-based synthesis represents a fundamentally different paradigm: rather than producing one sequence per column, it synthesizes thousands to millions of unique sequences in parallel on a single chip. In modern electrochemical or photolithographic microarray platforms, each feature (pixel) on the chip surface corresponds to one unique sequence. Nucleotides are deposited selectively at each feature through light- or electrochemically-directed chemistry, building all sequences simultaneously on the chip surface.

Key characteristics of microarray-based synthesis:

• A single chip run produces thousands to millions of distinct sequences simultaneously — Dynegene's platform generates up to 4.35 million unique oligos per chip
• Oligos are synthesized at femtomole scale per feature, meaning each unique sequence is present in extremely small quantity per chip run
• Maximum oligo length on advanced platforms (including Dynegene's honeycomb pixel architecture) reaches 350 nt per oligo — significantly longer than conventional arrays
• Because purification of individual sequences from a chip is not practical, microarray synthesis relies on error correction algorithms and enzymatic error filtering (e.g., mismatch endonuclease treatment) applied to the pooled output
• Cost per base pair at scale is orders of magnitude lower than column synthesis — enabling library-scale projects that would be economically impossible via column synthesis

Microarray synthesis is the enabling technology for massively parallel DNA libraries — CRISPR sgRNA libraries, antibody diversity libraries, variant effect mapping panels, oligo pools for synthetic biology, and high-volume gene fragment production, such as the workflows supported by Dynegene's Gene Fragments service.

Direct Technical Comparison

Parameter	Column-Based Synthesis	Microarray-Based Synthesis
Sequences per run	1 per column	Up to 4.35 million per chip (Dynegene)
Output scale per sequence	Nanomole–micromole	Femtomole–picomole
Maximum oligo length	~150–300 nt (standard); up to 200 nt high-quality	Up to 350 nt (Dynegene platform)
Synthesis error rate	~1:1,000–1:10,000 /bp (raw); improved by HPLC purification	~1:500–1:5,000 /bp (raw); improved by error correction
Purification method	HPLC, PAGE, or desalting per oligo	Enzymatic error correction on pooled output
Cost per base pair (high volume)	Higher (scales poorly with sequence diversity)	Lower (scales favorably with sequence diversity)
Sequence diversity capacity	Limited by number of columns running in parallel	Essentially unlimited within chip capacity
Ideal batch size	1–100 unique sequences	100–4,350,000 unique sequences
Delivery format	Individual oligos, purified	Pooled (sub-pool or mini-pool) or individual post-amplification
Best application	Primers, probes, single sgRNAs, diagnostic oligos	CRISPR libraries, antibody libraries, gene fragment pools, oligo pools

Where Column-Based Synthesis Excels

Despite the rise of microarray platforms, column-based synthesis retains clear advantages in specific scenarios:

High-Purity Individual Oligos

When a single sequence needs to be produced at high purity (> 90–95% full-length, sequence-correct) and in large quantities (micromole scale), column synthesis with HPLC purification remains unmatched. Therapeutic antisense oligonucleotides (ASOs), siRNA duplexes for clinical use, and diagnostic primers destined for regulatory-grade assays all typically require column synthesis with documented purity certificates.

Short, Simple Sequences

For standard PCR primers (18–25 nt), real-time PCR probes (20–30 nt), or other short, simple sequences ordered one at a time, column synthesis is the most cost-efficient and fastest route. The overhead associated with microarray-based synthesis — chip setup, error correction, amplification, and pool deconvolution — makes it impractical for single-oligo orders.

Long Individual Oligos with High Purity

For long single-sequence oligos (100–200 nt) requiring gel or HPLC purification, column synthesis with post-synthesis purification is the only practical route to achieving > 85% full-length purity. Microarray synthesis of equivalent-length oligos yields femtomoles of material per feature, making individual purification economically non-viable.

Where Microarray-Based Synthesis Excels

Microarray synthesis defines the frontier of what is possible in high-throughput synthetic DNA:

Library-Scale Gene Fragment Production

The defining advantage of microarray synthesis is sequence diversity at scale. A single chip run on Dynegene's platform can produce up to 4.35 million unique sequences — enabling the synthesis of entire CRISPR libraries, antibody repertoires, or variant libraries in a single production run that would require 4.35 million individual column runs to replicate. For gene fragment synthesis specifically, this means that research programs requiring hundreds to thousands of sequence variants (promoter libraries, CDR variant panels, codon usage studies) can be fulfilled at a fraction of the cost of equivalent column-based orders.

Lower Cost Per Base Pair at Scale

The cost economics of microarray synthesis improve dramatically as the number of unique sequences increases. While column synthesis cost is roughly proportional to the number of unique sequences (each requiring a dedicated column and reagents), microarray synthesis cost is dominated by chip setup and run costs that are essentially fixed regardless of how many unique sequences are included on the chip. This means:

• For 100 sequences: column synthesis may be cost-competitive
• For 1,000 sequences: microarray synthesis typically offers 5–10× cost reduction
• For 100,000+ sequences: microarray synthesis is the only economically viable option

For a deeper breakdown of how these economics translate into actual quotes, see Dynegene's gene fragment synthesis cost guide.

Longer Oligos with Superior Assembly Efficiency

Dynegene's microarray platform synthesizes oligos up to 350 nt in length — substantially longer than the 40–120 nt that most conventional microarray platforms support. Longer oligos are advantageous for gene fragment assembly because:

• Fewer junction points are required per kilobase of assembled sequence
• Each junction point is a potential site for assembly errors; fewer junctions means lower cumulative error probability
• Longer assembly building blocks allow more complex secondary structure elements to be captured within a single synthetic oligo, improving assembly fidelity for GC-rich or structured sequences

Sub-Pool and Mini-Pool Delivery Flexibility

Unlike column synthesis, which delivers each sequence individually, microarray synthesis supports configurable pool delivery formats. Dynegene's sub-pool mode maximizes throughput by grouping related sequences for parallel delivery, while mini-pool mode prioritizes speed for smaller, time-sensitive projects. This configurability enables research programs to match delivery format to experimental design without changing the underlying synthesis platform.

Error Rate: Understanding the Difference

One of the most common concerns about microarray-based synthesis is error rate. This deserves careful consideration:

Raw Error Rates

Unprocessed microarray synthesis typically yields error rates of 1 error per 500–2,000 bp — higher than the 1:1,000–1:10,000 achievable with HPLC-purified column synthesis. This difference arises because column synthesis products are purified at the individual-sequence level, while microarray synthesis products are used as pools without per-sequence purification.

Error Correction Closes the Gap

Modern microarray-based synthesis pipelines incorporate multiple layers of error reduction:

• Enzymatic error correction (EEC): Mismatch endonucleases (e.g., T7 Endonuclease I, MutS protein) selectively cleave heteroduplex DNA at sites of base-pair mismatch, removing error-containing sequences from the pool. A single round of EEC typically reduces error rates by 5–10×
• Next-generation error correction: Sequencing-based selection followed by selective amplification of error-free sequences can push effective error rates below 1:10,000 /bp for premium gene fragment tiers
• Longer oligos reduce junction errors: By using 350 nt oligos (as on the Dynegene platform), the number of ligation/assembly junctions per assembled fragment is minimized, reducing the total error accumulation per kilobase of product

For most gene fragment applications — cloning, CRISPR donors, antibody variant screening, mRNA templates — post-error-correction microarray synthesis quality is fully adequate, and the assembled constructs are fully compatible with standard Gibson Assembly cloning workflows. For applications requiring the absolute highest accuracy (e.g., diagnostic reference standards, clinical-grade constructs), clonal verification by NGS sequencing provides a final quality gate regardless of synthesis platform.

Choosing the Right Platform for Your Project

The decision between microarray and column synthesis for gene fragments reduces to three key factors:

1. Number of Unique Sequences

Number of Unique Sequences	Recommended Platform
1–50	Column-based synthesis
50–500	Depends on length and purity requirements
500–10,000	Microarray synthesis (clear cost advantage)
> 10,000	Microarray synthesis (only viable option)

2. Required Output Quantity Per Sequence

• > 1 nmol per sequence required: Column synthesis
• Femtomole to low pmol acceptable (library applications): Microarray synthesis

3. Downstream Application

Application	Preferred Platform
PCR primers, probes	Column synthesis
Single gene fragment for cloning	Column or microarray (comparable)
Panel of 10–100 gene fragment variants	Microarray (cost advantage)
CRISPR library (thousands of sgRNAs)	Microarray synthesis only
Antibody VH/VL diversity library	Microarray synthesis only
mRNA vaccine antigen variant screening	Microarray synthesis (parallel design testing)
Diagnostic-grade individual oligo	Column synthesis (HPLC-purified)

Dynegene's Next-Generation Microarray Platform

Dynegene's synthesis infrastructure represents the state of the art in microarray-based gene fragment production. The platform's honeycomb pixel architecture enables:

• Up to 350 nt per oligo — the longest oligo length available on a microarray platform, reducing assembly junction counts and improving assembled fragment fidelity
• Up to 4.35 million unique sequences per chip — enabling true library-scale synthesis for the most demanding research programs
• Up to 1 Gb of synthesized DNA per production run — supporting industrial OEM volumes alongside academic research orders
• Sub-Pool and Mini-Pool delivery modes — configurable throughput-versus-speed tradeoffs without changing platform infrastructure

This combination of long-oligo capability, ultra-high throughput, and flexible delivery formats positions Dynegene's Gene Fragments service to support projects across the full spectrum — from individual researcher orders to industrial-scale synthetic DNA production.

For projects requiring the complementary capabilities of target enrichment alongside gene fragment synthesis, Dynegene's NGS Custom Probes and Whole Exome Sequencing Probes complete the portfolio with hybridization-grade reagents produced on the same high-quality synthesis infrastructure.

Frequently Asked Questions

Q: Are microarray-synthesized gene fragments suitable for cloning and expression?
Yes. Post-error-correction microarray gene fragments are routinely used for Gibson Assembly cloning, Golden Gate Assembly, and direct expression after ligation into vectors. The key requirement is that at least one sequence-correct molecule is present in the delivered pool — this is readily achieved even at femtomole-scale synthesis yields when combined with PCR amplification.

Q: Can microarray synthesis produce fragments longer than 3,000 bp?
Directly, no — microarray synthesis produces oligos (up to 350 nt on Dynegene's platform) that are then assembled into longer gene fragments by PCR-based assembly (PCA) or ligation assembly. Fragments up to 3,000 bp are routinely produced this way; longer constructs may require hierarchical assembly combining multiple gene fragments.

Q: Is microarray synthesis suitable for GMP or regulated applications?
Microarray-synthesized gene fragments can be used in regulated research and IVD development contexts when accompanied by appropriate quality documentation (COA, sequence verification reports). For clinical manufacturing (GMP production), additional validation steps and documentation are typically required regardless of synthesis platform.

Q: How does Dynegene ensure sequence accuracy on its microarray platform?
Dynegene employs enzymatic error correction combined with optional NGS-based sequence verification for premium fragment tiers. The 350 nt oligo length reduces the number of assembly junctions per fragment, inherently lowering the accumulated error rate compared to platforms using shorter (40–120 nt) oligos.

Evaluate the right synthesis platform for your project. Contact Dynegene at info2@dynegene.com or visit dynegene.com/en/detail-464.html to discuss how microarray-based gene fragment synthesis can support your research scale and application requirements.